74 / 164
334
9.
Bianchi C, Bianchi T, Bucconi S. Malignant mesothelioma
of the pleura in nonagenarian patients. Tumori. 2011
Mar-Apr;97(2):156-9.
10.
Robinson BW, Lake RA. Advances in malignant mesothelioma.
N Engl J Med 2005;353:1591–1603.
11.
Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural
mesothelioma: evaluation with CT, MR imaging, and PET.
Radiographics 2004;24:105–119.
12.
Gill RR, Richards WG, Yeap BY, et al. Epithelial malignant
pleural mesothelioma after extrapleural pneumonectomy:
stratification of survival with CT-derived tumor volume. AJR.
2012;198:359-63.
13.
Plathow C, Staab A, Schmaehl A, et al. Computed tomography,
positron
emission
tomography,
positron
emission
tomography/computed tomography, andmagnetic resonance
imaging for staging of limited pleural mesothelioma: initial
results. Invest Radiol 2008;43:737-44.
14.
Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection
margins, extrapleural nodal status and cell type determine
postoperative long term survival in trimodality therapy of
malignant pleural mesothelioma: results in 183 patients. J
Thorac Cardiovasc Surg. 1999;117:54-65.
15.
Flores RM, Routledge T, Seshan VE, et al.The impact of lymph
node station on survival in 348 patients with surgically
resected malignant pleural mesothelioma: implications for
revision of the American Joint Committee on Cancer staging
system. J Thorac Cardiovasc Surg. 2008;136:605-10.
16.
Sharif S, Zahid I, Routledge T, et al. Does positron emission
tomography offer prognostic information in malignant
pleural mesothelioma? Interact Cardiovasc Thorac Surg
2011;12:806-11.
17.
Flores RM, Akhurst T, Gonen M, et al. Positron emission
tomography predicts survival in malignant pleural
mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763-8.
18.
Klabatsa A1, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski
L, Cook GJ. The association of 18F-FDG PET/CT parameters
with survival in malignant pleural mesothelioma. Eur J Nucl
Med Mol Imaging. 2014 Feb;41(2):276-82.
19.
Basu S, Saboury B, Torigian DA, Alavi A. Current evidence
base of FDG-PET/CT imaging in the clinical management
of malignant pleural mesothelioma: emerging significance
of image segmentation and global disease assessment. Mol
Imaging Biol. 2011;13:801-11.
20.
Zahid I, Sharif S, Routledge T, et al. What is the best way
to diagnose and stage malignant pleural mesothelioma?
Interact Cardiovasc Thorac Surg 2011;12:254-9.
21.
Shinohara T, Shiota N, Kume M, Hamada N, Naruse K,
Ogushi F. Asymptomatic primary tuberculous pleurisy with
intense 18-fluorodeoxyglucose uptake mimicking malignant
mesothelioma. BMC Infect Dis. 2013 Jan 14;13:12.
22.
Abe Y, Tamura K, Sakata I, et al. Usefulness of (18)F-FDG
positron emission tomography/computed tomography for
the diagnosis of pyothorax-associated lymphoma: A report of
three cases. Oncol Lett. 2010 Sep;1(5):833-6.
23.
Vandemoortele T, Laroumagne S, Roca E, et al. Positive FDG-PET/
CT of the pleura twenty years after talc pleurodesis: Three cases
of benign talcoma. Respiration 2014;87(3):243-8.
24.
Armato SG 3rd, Labby ZE, Coolen J, et al.Imaging in pleural
mesothelioma: a review of the 11th International Conference
of the International Mesothelioma Interest Group. Lung
Cancer. 2013 Nov;82(2):190-6.
25.
Fujimoto N, Gemba K, Asano M, et al. Hyaluronic acid
in the pleural fluid of patients with malignant pleural
mesothelioma. Respir Investig. 2013;51:92-7.
26.
Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural
effusion hyaluronic acid as a prognostic marker in pleural
malignant mesothelioma. Lung Cancer. 2013;82:491-8.
27.
Herndon JE, Green MR, Chahinian AP, et al. Factors predictive
of survival among 337 patients with mesothelioma treated
between 1984 and 1994 by the Cancer and Leukemia Group
B. Chest. 1998;113:723-31.
28.
Sahn SA, Good JT. Pleural fluid pH in malignant effusions:
diagnostic, prognostic, and therapeutic implications. Ann
Intern Med 1988;108:345-9.
29.
Rodriguez-Panadero F, Lopez-Mejias J. Survival time of
patients with pleural metastatic carcinoma predicted by
glucose and pH studies. Chest. 1989 Feb;95(2):320-4.
30.
Sanchez-Armengol A, Rodriguez-Panadero F. Survival and
talc pleurodesis in metastatic pleural carcinoma, revisited.
Report of 125 cases. Chest. 1993 Nov;104(5):1482-5.
31.
Fysh ET, Bielsa S, Budgeon CA, et al. Predictors of Clinical Use
of Pleurodesis and/or Indwelling Pleural Catheter Therapy for
Malignant Pleural Effusion. Chest. 2014 Dec 4. doi: 10.1378/
chest.14-1701. [Epub ahead of print]
32.
Ogata Y, Aoe K, Hiraki A, et al. Is adenosine deaminase in
pleural fluid a useful marker for differentiating tuberculosis
from lung cancer or mesothelioma in Japan, a country with
intermediate incidence of tuberculosis? Acta Med Okayama.
2011;65:259-63.
33.
Rodríguez-Panadero F, Pérez MA, Moya MA, Cruz MI. Manejo
de la patología pleural. Arch Bronconeumol. 2009;45 Suppl
3:22-7.
34.
Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial
hyperplasia vs mesothelioma, including mesothelioma in
situ: a brief review. Am J Clin Pathol. 1998;110:397-404.
35.
Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe
S. Challenges and controversies in the diagnosis of
mesothelioma: Part 1. Cytology-only diagnosis, biopsies,
immunohistochemistry,
discrimination
between
mesothelioma and reactive mesothelial hyperplasia, and
biomarkers. J Clin Pathol. 2013;66:847-53.
36.
British Thoracic Society Standards of Care Committee BTS
statement on malignant mesothelioma in the UK, 2007.
Thorax. 2007;62Suppl 2:ii1-ii19.
37.
Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic
diagnosis of malignant mesothelioma: 2012 update of the
consensus statement from the International Mesothelioma
Interest Group. Arch Pathol Lab Med. 2013;137:647-67.
[REV. MED. CLIN. CONDES - 2015; 26(3) 325-337]